Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  INSM - Insmed - Deel 13

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

INSM - Insmed - Deel 13

1.310 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 66 »» | Laatste | Omlaag ↓
  3. [verwijderd] 7 februari 2007 21:54
    ...wij weten wat hier werkt!

    The associated features of lipodystrophy - and again, this begins to sound to me like a syndrome - insulin resistant diabetes and hypertriglyceridemia are typically associated with these non-HIV associated lipodystrophy. As I pointed out, fat accumulation can occur in unaffected areas, such as the head and neck. For the infectious disease individuals in the audience, partial lipodystrophy has been reported following febrile illnesses associated with collagen or vascular diseases and deficiency in C3. Now the HIV world became alerted to lipodystrophy in this report in AIDS by Carr and Cooper from Australia. Illustrated here is a patient they describe as typically losing fat in the face. You can see this loss of fat in the sub-zygomatic area. It’s fairly dramatic. This individual also had lost fat in the periphery but a tendency to retain fat, or maybe even accumulate it, in the abdominal area. They actually found this kind of pattern, they said, in about 65% of 116 patients that they surveyed in their clinic who were on protease inhibitors and only 3 or 4% of patients who were not on protease inhibitors. That is really an astounding finding. So we have gone now to try to get an idea of prevalence of this complaint and reviewed this six or seven or eight reports that have appeared either at Geneva in abstract or in a couple of papers that have been published. What strikes us as really amazing here is the difference in prevalence estimates. Ranging from 2% in one fairly large population - 272 chart reviewed - up to 65 or 75% from the group in Australia. I think that probably the truth lies somewhere in between, but where it is and how close it is to the lower or higher figure, we don’t know. There was just a meeting in Chicago and planning for a NIH study. The ACTG is going to do a prevalence study and is probably going to take a hard look at several thousand patients to try to get a feeling for how frequently this problem occurs. My final slide is, I think, a list of issues. I think we need to develop the uniform case definition of fat redistribution disorders. Is it one syndrome or overlaps of several? We need to identify the mechanisms underlying these metabolic and body composition changes. The relationship, if any, to specific anti-retroviral regimens, and what their clinical sequelae are. Should we be worried about this? People are actually stopping therapy because of their concerns about their lipid profiles, obviously in people who are in effective anti-retrovirals that is not something that we want to recommend. And finally we need to define the optimal management. I can say that there have been a couple of case reports or anecdotal reports of the use of growth hormone, of anabolic steroids, of insulin sensitizing drugs like troglitazone, or metformin. And yet no careful studies have yet been done to really let us know whether these are going to be effective and safe. There are reasons that for example growth hormone, has to be given with care because of its tendency to exacerbate hyperlipidemia and insulin resistance, which is known from the non-HIV world.
    rxdic.com/publications-and-articles/m...

    Geluk, F.
  15. [verwijderd] 8 februari 2007 09:55
    quote:

    magie228 schreef:

    waarom stijgt het? ik zie geen nieuws!
    Shorts die coveren, of grote durfkapitalisten die nu een positie innemen die speculeren op geen injunction. Plus vergeet niet dat we binnen 2 weken nieuws van de EMEA kunnen verwachten. Dus sta niet raar te kijken als we zo weer op 1,50 staan.
1.310 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 66 »» | Laatste |Omhoog ↑

Direct naar Forum

Indices

AEX 891,90 +0,50%
EUR/USD 1,0784 +0,18%
FTSE 100 8.213,49 0,00%
Germany40^ 18.161,40 +0,89%
Gold spot 2.328,89 +1,18%
NY-Nasdaq Composite 16.156,33 +1,99%

Stijgers

Umicore
+3,86%
Solvay
+1,92%
Aperam
+1,85%
Econoc...
+1,80%
D'IETE...
+1,73%

Dalers

Colruyt
-2,72%
Barco
-1,85%
VGP
-1,69%
bpost
-1,30%
Ontex
-1,10%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!